Certolizumab accepted by NICE

A PEGylated antibody against tumour necrosis factor (TNF) can now be prescribed on the NHS for rheumatoid arthritis (RA).

Use of certolizumab pegol (Cimzia) on the NHS is subject to the same restrictions as the other TNF inhibitors adalimumab, etanercept and infliximab.

Furthermore, NICE acceptance is contingent on the manufacturer, UCB Pharma, providing the first 12 weeks of treatment for free.

Certolizumab pegol can be used in adults who meet both of the following criteria:

  • Active RA with disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, one month apart
  • Previous trials of two DMARDs, including methotrexate (unless contraindicated). DMARD trials are usually for 6 months with 2 months at standard dose.

Patients on certolizumab pegol, adalimumab, etanercept or infliximab should normally receive methotrexate. If methotrexate is inappropriate or not tolerated, certolizumab, adalimumab and etanercept may be given as monotherapy.

Treatment should only be continued if there is an adequate response (DAS28 improvement of at least 1.2) 6 months after initiating therapy. Response should be monitored at least every 6 months and treatment should be discontinued if an adequate response is not maintained.

For patients who are intolerant of treatment before the initial 6-month assessment, prescribers should consider an alternative TNF inhibitor.

Treatment should normally be initiated with the least expensive drug, and escalation above the licensed starting dose is not recommended.

Treatment of severe, active and progressive RA is not recommended in adults who have not previously received methotrexate or other DMARDs.

View Cimzia drug record

NICE guidance on certolizumab pegol

NICE guidance on adalimumab, etanercept and infliximab


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more